People are anxious over potential harmful effects related to chromosomal, genetic, and hereditary, leads to infertility-related problems such as PCOS and low sperm count disorders. PGD helps in preventing inheritance of diseases and thereby eliminating the chances of pregnancy termination.
Preimplantation Genetic Diagnosis (PGD) market size was valued at $79 million, and is expected to reach $121 million by 2022, supported by a CAGR of 6.14%. Preimplantation genetic diagnosis (PGD) also referred as embryo screening, is a branch of genetics involves in genetic testing of embryo through In-Vitro fertilization (IVF). PGD eliminates risk of selective pregnancy termination for couples who are at substantial risk of transferring serious genetic, chromosomal or hereditary disorders such as spinal muscular atrophy and cystic fibrosis.
The world PGD market is expected to witness notable growth in the coming years owning to the rising prevalence of genetic, hereditary and chromosomal diseases. Moreover, PGD have high chances of conceiving healthy embryos. However, the high costs incurred in the PGD technologies hamper the growth of the market. Moreover, stringent government regulations and ethical concerns also obstruct the growth of the market. In coming years, there would be increase in adoption of PGD worldwide owning to the various applications of PGD for development of healthy embryo.
Get the PDF brochure of this market study@ https://www.alliedmarketresearch.com/request-sample/1470
At present, chromosomal abnormalities segment has witnessed large-scale adoption of PGD market. Single gene disorders, aneuploidy and X-linked disease are some of the other segments in world PGD market. These segments are anticipated to witness increase in market share due to growing genetic, hereditary and chromosomal diseases. However, stringent government regulations related to use of PGD have hindered the market growth of PGD market. Furthermore, gender selection is anticipated grow owning to increasing gender imbalance. However, stringent government regulations and restriction of gender selection have hindered the market growth of this segment.
The significant impacting factors include effective embryo development and diverse PGD applications such as, overcoming infertility, chromosomal and hereditary disorders. All these factors collectively create opportunities for the market growth whilst some of the factors pose limitations in the market. However, each factor would have its definite impact on the market during the forecast period.